Climb Bio, Inc. — Form 8-K
Filed July 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On June 29, 2026, Andrew Levin resigned from Climb Bio's board effective immediately. Breanna O'Reilly, Ph.D., was elected as a director the same day. O'Reilly received an initial grant of 70,284 stock options at $13.36/share (vesting over 3 years) plus $40,000 annual cash retainer and standard equity grants.
Why this rating
Routine board rotation at micro-cap ($44.8M); typical director replacement with standard compensation; no material business impact.
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.